

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

[ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)



This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

March 14, 2024

### Presentation at 3rd regional symposium on Myelodysplastic syndrome

Kanagawa, Japan,

March 14, 2024—Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; President: Hiroshi Miyake) is pleased to announce that our CSO Daisuke Morishita and Professor Seiji Ogawa of Kyoto University, Japan, will jointly present the data of CTX-712 at the 3rd regional symposium on Myelodysplastic syndrome(MDS) on March 15-16, 2024. This symposium will cover hot topics in MDS from a basic, translational, and clinical point of view. As in the previous regional symposiums, the main lectures will be delivered by recognized international leaders in the field. Please refer to the following link for further information.  
<https://mdsr.kenes.com/>

### **About Chordia Therapeutics**

Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, is developing novel cancer therapies. Chordia's lead asset, CLK inhibitor CTX-712, is currently in Phase 1 clinical study in Japan and Phase1/2 clinical study in the US. CTX-712 potentially targets vulnerabilities in cancer and could benefits patients with various types of cancer. In addition to CTX-712, Chordia is researching several preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)